Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07546500 · ClinicalTrials.gov registry record · Phase 3
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
A Phase 3 study, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
NCT07546500 is a Phase 3 study that is actively recruiting participants, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 420 participants.
The verdict
NCT07546500, a Phase 3 study, is actively recruiting participants, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
Study Summary
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.
Interventions
- DRUG Azenosertib
- DRUG Investigator's choice of Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07546500
The ClinicalTrials.gov registry entry for NCT07546500 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azenosertib is the first listed.
NCT07546500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07546500 about?
NCT07546500 is a clinical study titled "A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression". This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.
What is the current status of trial NCT07546500?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2026-04-17. Estimated completion is 2030-04-30.
What interventions are being tested in trial NCT07546500?
The interventions under investigation include: Azenosertib (DRUG), Investigator's choice of Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07546500?
This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.